Title: The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
Lead Author: Hans Gelderblom
Abstract: 11504
Oral presentation: Saturday, May 30, 2026 (Session time: 4:12 PM – 4:24 PM CDT)
Title: Phase 1 study of the tetravalent death receptor 5 agonist ozekibart (INBRX-109) combined with chemotherapy in locally advanced or metastatic, unresectable colorectal adenocarcinoma (CRC).
Lead Author: Hazel Lote
Abstract: 3533
Poster presentation: Saturday, May 30, 2026 (Session time: 9:00 AM – 12:00 PM CDT)
